1.245USD+13.18%Mkt Cap: 24.35M USDP/E: —Last update: 2026-05-26
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap24.35M USD
Enterprise Value-428.21K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-83.98M USD
Revenue/Share—
Last Price1.245 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees38
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.91
PEG—
EV/EBITDA0.01
EV/Revenue—
P/S—
P/B-0.17
EPS (TTM)-10.50
EPS (Forward)-1.17
52W Range
0.79001% of range45.50
52W High45.50 USD
52W Low0.7900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE235.14%
ROA-89.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.42M USD
CapEx (TTM)352.00K USD
FCF Margin—
FCF Yield-125.56%
Net Debt-17.87M USD
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity-0.52
Current Ratio2.92
Quick Ratio2.07
Book Value/Sh-6.4090 USD
Cash/Share1.114 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 13, 2026
Analyst Consensus
Rating—
Target (Mean)0.0000 USD
Target Range0.0000 USD – 0.0000 USD
# Analysts1
Ownership
Shares Out.19.56M
Float15.71M
Insiders3.19%
Institutions9.98%
Short Interest
Short Ratio0.2d
Short % Float10.99%
Short % Out.10.95%
Shares Short1.78M
Short (prev mo.)1.38M
Technical
SMA 501.176 (+5.9%)
SMA 20014.50 (-91.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.10M
Avg Vol (10d)3.19M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—